Vladimir Coric, MD
DownloadHi-Res Photo
About
Appointments
Education & Training
- Fellowship in Forensic Psychiatry
- Yale University School of Medicine (2001)
- Chief Resident, Post-Traumatic Stress Disorder Firm
- National Center for PTSD, VA Connecticut Healthcare System (2000)
- Program-Wide Chief Resident
- Yale University School of Medicine (2000)
- Yale Psychiatry Residency Training Program
- Yale University School of Medicine (2000)
- MD
- Wake Forest University (1996)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Vladimir Coric's published research.
Publications Timeline
A big-picture view of Vladimir Coric's research output by year.
Angeli Landeros-Weisenberger, MD
Michael Bloch, MD, MS
Dan Oren, MD, BS
Evangelos K. Oikonomou, MD, DPhil
John Krystal, MD
Rohan Khera, MD, MS
90Publications
2,422Citations
Publications
Video-Based Kinematic Analysis of Movement Quality in a Phase 3 Clinical Trial of Troriluzole in Adults with Spinocerebellar Ataxia: A Post Hoc Analysis
L’Italien G, Oikonomou E, Khera R, Potashman M, Beiner M, Maclaine G, Schmahmann J, Perlman S, Coric V. Video-Based Kinematic Analysis of Movement Quality in a Phase 3 Clinical Trial of Troriluzole in Adults with Spinocerebellar Ataxia: A Post Hoc Analysis. Neurology And Therapy 2024, 1-15. PMID: 38814532, DOI: 10.1007/s40120-024-00625-6.Peer-Reviewed Original ResearchAltmetricConceptsMovement qualityVideo-based kinematic analysisGait stability measuresTandem walking taskRating of AtaxiaGait qualityGait assessmentGait parametersTandem walkingWalking assessmentsWalking taskSpinocerebellar ataxiaVideo-based assessmentClinical expertiseNatural walkingRandomized participantsGaitHigh riskPost hoc analysisStandardized scalesAdultsWalkingParticipantsHoc analysisPhase 3Re-weighting MDS-UPDRS Part II Items for Optimal Sensitivity to Parkinson’s Disease Progression Using Parkinson’s Progression Markers Initiative Natural History Data (P11-3.012)
Dickson S, Rogula B, Dubow J, Kozauer N, Powell L, Potashman M, Crimin K, O’Keefe P, Korol E, Crabtree M, Nagase F, Coric V, Hendrix S, L’Italien G. Re-weighting MDS-UPDRS Part II Items for Optimal Sensitivity to Parkinson’s Disease Progression Using Parkinson’s Progression Markers Initiative Natural History Data (P11-3.012). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204570.Peer-Reviewed Original ResearchFunctional Impairments in Patients with KCNQ2-DEE: Associations Among Key Clinical Features (P1-1.007)
Berg A, Lerner J, Millichap J, L’Italien G, Coric V, Potashman M. Functional Impairments in Patients with KCNQ2-DEE: Associations Among Key Clinical Features (P1-1.007). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204827.Peer-Reviewed Original ResearchPsychometric Validation of the Modified-functional Scale for the Assessment and Rating of Ataxia (P7-3.018)
Potashman M, Popoff E, Powell L, Beiner M, Mackenzie A, Coric V, Schmahmann J, L’Italien G. Psychometric Validation of the Modified-functional Scale for the Assessment and Rating of Ataxia (P7-3.018). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204549.Peer-Reviewed Original ResearchRe-weighting MDS-UPDRS Motor Items for Optimal Sensitivity to Parkinson’s Disease Progression in Untreated Patients Using Parkinson’s Progression Markers Initiative Data (S2.004)
L’Italien G, Dickson S, Rogula B, Dubow J, Kozauer N, Powell L, Potashman M, Crimin K, O’Keefe P, Korol E, Crabtree M, Nagase F, Coric V, Hendrix S. Re-weighting MDS-UPDRS Motor Items for Optimal Sensitivity to Parkinson’s Disease Progression in Untreated Patients Using Parkinson’s Progression Markers Initiative Data (S2.004). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204569.Peer-Reviewed Original ResearchNext Generation Prodrug Troriluzole: Increased Bioavailability of Riluzole with No Food Effect in Healthy Subjects (S5.006)
Sevinsky H, Rozakis R, Nepomuceno T, Malatesta J, Awsare B, Ashbrenner E, Kaplita S, Gentile K, Hussey E, Qureshi I, Coric V, Bertz R. Next Generation Prodrug Troriluzole: Increased Bioavailability of Riluzole with No Food Effect in Healthy Subjects (S5.006). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205022.Peer-Reviewed Original ResearchNo Clinically Relevant Effects of Hepatic Impairment on the Pharmacokinetics of a Next Generation Prodrug Troriluzole (P4-4.014)
Bertz R, Rozakis R, Donohue M, Sevinsky H, Awsare B, Kaplita S, Hussey E, Qureshi I, Coric V. No Clinically Relevant Effects of Hepatic Impairment on the Pharmacokinetics of a Next Generation Prodrug Troriluzole (P4-4.014). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000206134.Peer-Reviewed Original ResearchTroriluzole Exhibits Favorable Hepatic Safety Profile Across a Diverse Range of Disorders (P4-4.013)
Qureshi I, Beiner M, Bertz R, Kaplita S, Yang R, Munivar A, Stock D, Wirtz V, Coric V. Troriluzole Exhibits Favorable Hepatic Safety Profile Across a Diverse Range of Disorders (P4-4.013). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000206182.Peer-Reviewed Original ResearchDeterminants of Health-related Quality of Life of Patients with Focal Epilepsy: A Systematic Literature Review (P9-1.016)
Marcin C, Engelhart P, Lerner J, Dill D, L’Italien G, Coric V, Matsumoto J, Potashman M. Determinants of Health-related Quality of Life of Patients with Focal Epilepsy: A Systematic Literature Review (P9-1.016). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204828.Peer-Reviewed Original ResearchMatching-adjusted Indirect Comparison of Troriluzole Versus Untreated Natural History Cohort in Spinocerebellar Ataxia (S35.009)
Beiner M, Powell L, Rogula B, Potashman M, Wirtz V, Schmahmann J, Perlman S, Coric V, L’Italien G. Matching-adjusted Indirect Comparison of Troriluzole Versus Untreated Natural History Cohort in Spinocerebellar Ataxia (S35.009). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205167.Peer-Reviewed Original Research
Links & Media
News
- January 09, 2020
Biohaven Pharmaceuticals Named Murphy's 'Innovator of the Month'
- June 14, 2018
Coric named Ernst & Young Entrepreneur of the Year in New York region
- November 04, 2016
Biohaven Pharmaceuticals secures new round of financing
- August 14, 2012Source: HealthDay
Genetic studies give clues to Tourette syndrome, OCD